Free tool
FAERS Monitor: Nerlynx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208051 or its brand name (Nerlynx, Neratinib Maleate). Reports on generic versions are filed under their own applications.
Reports
2,319
Serious
1,373
59% of reports
Hospitalization
685
Death reported
364
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,262
- nausea557
- fatigue474
- off label use414
- vomiting317
- constipation279
- decreased appetite257
- death199
- disease progression157
- dehydration148
- weight decreased139
- abdominal pain119
- headache116
- asthenia104
- dizziness103
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 3 |
| 2010 | 23 |
| 2011 | 10 |
| 2012 | 13 |
| 2013 | 16 |
| 2014 | 8 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 143 |
| 2018 | 739 |
| 2019 | 241 |
| 2020 | 255 |
| 2021 | 280 |
| 2022 | 170 |
| 2023 | 147 |
| 2024 | 124 |
| 2025 | 84 |
| 2026 | 57 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,840 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diarrhoeaSignal | 1,262 | 17.8 | 17.1 | 20,541 |
| disease progressionSignal | 157 | 12.0 | 10.4 | 1,587 |
| constipationSignal | 279 | 11.6 | 10.4 | 2,721 |
| dehydrationSignal | 148 | 10.1 | 8.6 | 1,207 |
| decreased appetiteSignal | 257 | 10.0 | 9.0 | 2,105 |
| nauseaSignal | 557 | 6.4 | 5.9 | 2,622 |
| vomitingSignal | 317 | 6.1 | 5.5 | 1,382 |
| fatigueSignal | 474 | 5.5 | 5.1 | 1,818 |
| abdominal painSignal | 119 | 4.6 | 3.9 | 340 |
| weight decreasedSignal | 139 | 4.5 | 3.8 | 382 |
| off label useSignal | 414 | 4.3 | 3.9 | 1,086 |
| astheniaSignal | 104 | 2.5 | 2.1 | 95 |
| deathSignal | 199 | 2.1 | 1.8 | 118 |
| dizziness | 103 | 1.9 | 1.6 | 42 |
| headache | 116 | 1.7 | 1.4 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.